74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Geron Corp
Closed
SectorHealthcare
1.45
Overview
Share price change
24h
Min
1.43
Max
1.45
Income | 3.5M -16M |
|---|---|
Sales | 9.4M 49M |
Profit margin | -33.394 |
Employees | 229 |
EBITDA | 9.2M -7.6M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +97.24% upside |
Next Earnings | 6 Nov 2025 |
|---|
Market Cap | 97M 868M |
|---|---|
Previous open | 1.45 |
Previous close | 1.45 |
News Sentiment
By Acuity
45%
55%
143 / 374 Healthcare
Geron Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Geron Corp Forecast
Price Target
By TipRanks
97.24% upside
12 Months Forecast
Average 2.86 USD 97.24%
High 5 USD
Low 1 USD
Based on 8 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.
Sentiment
By Acuity
143 / 374 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
